echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > WHO updates the "New Crown Medication Guidelines", these 5 types of drugs are recommended for the treatment of mild symptoms

    WHO updates the "New Crown Medication Guidelines", these 5 types of drugs are recommended for the treatment of mild symptoms

    • Last Update: 2022-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Read only for medical professionals Reference clinical decision-making can be made simpler On April 21, 2022, the World Health Organization (WHO) updated the guidelines for COVID-19 treatment in the British Medical Journal (BMJ), one of the four leading medical journals.
    Guideline update [1], this guideline was first published in 2020
    .

    The updated guideline is very detailed and comprehensive, it assembles all key clinical trial evidence and relevant literature, especially the SOLIDARITY study conducted by WHO itself, and summarizes the treatment of COVID-19 in one figure (strongly recommended)
    .

    (General picture of WHO recommendation table) Highlight 1: Mild treatment, these 5 types of drugs are recommended In the latest WHO guidelines, for mild patients, the recommended and not recommended drugs are sorted as follows: The only important recommended treatment is Pfizer's Paxlovid; Conditions recommended are Molnupiravir, Remdesivir, and monoclonal antibodies Sotrovimab and REGN-COV2; ivermectin and cortisol hormone therapy are not recommended; the use of convalescent plasma, hydroxychloroquine and lopinavir is strongly discouraged Ritonavir tablets
    .

    (For the evaluation of Remdesivir) Highlight 2: Drug use in severe and critically ill patients For severe patients with pneumonia and hypoxia: Cortisol hormones, IL-6 inhibitors and JAK inhibitor Baricitinib are strongly recommended; but JAK1 is not recommended /2 inhibitors Ruxolitinib and Tofacitinib, ivermectin and convalescent serum; strongly against the use of hydroxychloroquine and lopinavir-ritonavir tablets
    .

    For critically ill patients with ARDS: cortisol hormone therapy only recommended; JAK1/2 inhibitors Ruxolitinib and Tofacitinib, ivermectin and convalescent serum not recommended; hydroxychloroquine and lopinavir-ritonavir are strongly discouraged slice
    .

    (Recommendation for hormones) Highlight 3: Paxlovid's medication indications and precautions The most important thing for this updated guideline is a comprehensive introduction to the use of Pfizer's Paxlovid indications, relevant evidence and precautions (see the figure below)
    .

    (For Paxlovid's evaluation) References: [1] https:// The original guideline, download the Doctor Station App and get it for free Source: Hanson Clinical Research Author: Dr.
    Wang Yuge Editor-in-Chief : Tian Wei proofread: Zang Hengjia's wonderful review of past issues confirmed that 3 injections of these two vaccines can prevent severe illness and death, and the protective power exceeds 97%! Can infection with the new crown be more protective than vaccination? Large-scale real-world research releases six mysteries of the new crown epidemic, when will they be solved? * The medical community strives for the accuracy and reliability of its published content when it is approved, but does not make any commitments and guarantees about the timeliness of the published content, and the accuracy and completeness of the cited materials (if any), and does not assume any any liability arising out of the date of such content, possible inaccuracies or incompleteness of the material cited
    .

    Relevant parties are requested to check separately when adopting or using it as a basis for decision-making
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.